IDEAYA Biosciences announces successful US FDA Type C meeting on Phase 2/3 registrational trial designs
IDYA•IDEAYA Biosciences said it had a successful US FDA Type C meeting on Phase 2/3 trial designs for IDE849. It plans a Phase 3 trial in neuroendocrine carcinoma subtypes and a single-arm cohort of 90 GEP-NEC patients for potential accelerated approval.




